BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, HC Wainwright Analyst Says

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) had its target price boosted by analysts at HC Wainwright from $49.00 to $53.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's price objective indicates a potential upside of 56.48% from the stock's previous close. HC Wainwright also issued estimates for BridgeBio Pharma's Q1 2025 earnings at ($1.01) EPS, Q2 2025 earnings at ($1.08) EPS, Q3 2025 earnings at ($1.02) EPS, Q4 2025 earnings at ($1.06) EPS, FY2025 earnings at ($4.17) EPS, Q1 2026 earnings at ($0.85) EPS, Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($2.98) EPS.

A number of other equities analysts have also recently commented on the stock. JPMorgan Chase & Co. lifted their price target on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a research note on Monday, March 24th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $95.00 price target on shares of BridgeBio Pharma in a report on Friday, February 21st. Scotiabank boosted their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the company a "sector outperform" rating in a report on Friday, February 21st. Evercore ISI increased their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research note on Monday, December 23rd. Finally, Citigroup boosted their target price on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a research note on Friday, February 21st. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat, BridgeBio Pharma presently has a consensus rating of "Moderate Buy" and an average target price of $53.00.

BridgeBio Pharma Price Performance

Shares of BridgeBio Pharma stock traded up $0.02 during trading on Tuesday, reaching $33.87. 1,410,624 shares of the stock traded hands, compared to its average volume of 2,271,192. The company has a market capitalization of $6.44 billion, a price-to-earnings ratio of -11.88 and a beta of 1.08. BridgeBio Pharma has a 52-week low of $21.62 and a 52-week high of $39.47. The business has a fifty day simple moving average of $33.79 and a two-hundred day simple moving average of $30.11.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million for the quarter, compared to analysts' expectations of $4.04 million. On average, research analysts predict that BridgeBio Pharma will post -3.67 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Andrea Ellis sold 30,000 shares of the company's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $34.05, for a total value of $1,021,500.00. Following the completion of the sale, the director now owns 12,000 shares of the company's stock, valued at approximately $408,600. This represents a 71.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Neil Kumar sold 326,932 shares of the business's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the transaction, the chief executive officer now owns 5,371,515 shares in the company, valued at $194,932,279.35. The trade was a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 9,694,739 shares of company stock valued at $327,308,651 in the last quarter. 24.66% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC lifted its stake in shares of BridgeBio Pharma by 85.8% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock valued at $28,000 after purchasing an additional 472 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of BridgeBio Pharma by 71.0% in the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company's stock worth $32,000 after acquiring an additional 382 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in shares of BridgeBio Pharma during the 4th quarter worth approximately $41,000. Sterling Capital Management LLC increased its holdings in BridgeBio Pharma by 554.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock valued at $49,000 after purchasing an additional 1,514 shares during the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in BridgeBio Pharma in the fourth quarter valued at approximately $109,000. 99.85% of the stock is currently owned by institutional investors and hedge funds.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.